A Phase 1/2 Open-Label, Multicenter Study of RAS(ON) inhibitors in Combination with Ivonescimab with or without Other Anti-Cancer Agents in Patients with Solid Tumors

Status

Not yet recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-524623-50-00

Enrollment

Registered

2026-06-29

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid Tumors

Brief summary

• Incidence of DLTs (Part 1 and Part 2 safety lead-ins only), • Incidence of AEs, TRAEs, SAEs, and clinically significant changes in laboratory test values and vital signs

Detailed description

• RAS(ON) inhibitor concentrations over time as applicable, • ORR and DOR per RECIST v1.1, • DCR, TTR and PFS per RECIST v1.1, • Ivonescimab serum concentrations over time as applicable, • Number and percentage of patients with detectable anti-ivonescimab antibody (ADA) at baseline and post treatment

Interventions

DRUGivonescimab

DRUGErbitux 5 mg/mL solution for infusion

DRUGCisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung

DRUGRMC-6291

DRUGDARAXONRASIB (RMC-6236)

DRUGCarboplatin Kabi 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung

DRUGPemetrexed 25 mg/ml concentrate for solution for infusion

DRUGRMC-9805

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
• Incidence of DLTs (Part 1 and Part 2 safety lead-ins only), • Incidence of AEs, TRAEs, SAEs, and clinically significant changes in laboratory test values and vital signs	—

Secondary

Measure	Time frame
• RAS(ON) inhibitor concentrations over time as applicable, • ORR and DOR per RECIST v1.1, • DCR, TTR and PFS per RECIST v1.1, • Ivonescimab serum concentrations over time as applicable, • Number and percentage of patients with detectable anti-ivonescimab antibody (ADA) at baseline and post treatment	—

Outcome results

None listed

Source: EU CTIS · Data processed: Jul 1, 2026